Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Galecto, Inc. (GLTO : NSDQ)

• Company Description    Galecto Inc. is a clinical stage biotechnology company with advanced programs in fibrosis and cancer centered on galectin-3 and LOXL2. The Company's pipeline includes an inhaled galectin-3 modulator currently in Phase 2b for the potential treatment of idiopathic pulmonary fibrosis. Galecto Inc. is headquarters in Copenhagen, Denmark. Number of Employees: 5

• Price / Volume Information    Yesterday's Closing Price: $3.47 Daily Weekly Monthly 20 Day Moving Average: 12,832 shares Shares Outstanding: 1.32 (millions) Market Capitalization: $4.59 (millions) Beta: 1.35 52 Week High: $16.07 52 Week Low: $2.01 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 3.58% -0.30% 12 Week 42.80% 20.11% Year To Date -25.38% -30.11%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 75 STATE STREET SUITE 100 - BOSTON,MA 02109 DNK ph: 45-7070-5210 fax: - None http://www.galecto.com

• General Corporate Information    Officers Hans T. Schambye - President; Chief Executive Officer and Director Carl Goldfischer - Chairman Lori Firmani - Interim Chief Financial Officer Jayson Dallas - Director Amit Munshi - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 36322Q206 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/11/25 Share - Related Items Shares Outstanding: 1.32 Most Recent Split Date: 8.00 (0.04:1) Beta: 1.35 Market Capitalization: $4.59 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-11.05 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.37 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 61.60% vs. Previous Quarter: 63.22% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -98.27 12/31/24 - -93.95 ROA 06/30/25 - - 03/31/25 - -84.29 12/31/24 - -81.65 Current Ratio 06/30/25 - - 03/31/25 - 9.62 12/31/24 - 14.07 Quick Ratio 06/30/25 - - 03/31/25 - 9.62 12/31/24 - 14.07 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 9.34 12/31/24 - 10.99 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©